Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build [Yahoo! Finance]
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
TheFly reported on January 9 that Stifel increased its price target on GH to $120 from $100 while maintaining a Buy rating. The firm anticipates strong volume and average selling price growth in 2026, with publication and reimbursement events that it claims will keep investors interested. Similarly, on the same day, Mizuho raised its price target on Guardant Health, Inc. (NASDAQ:GH) to $135 from $120 while maintaining an Outperform rating. Additionally, the firm revised its models for the diagnostics and medical device sectors. Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company focused on developing non-invasive liquid biopsy tests for cancer detection, treatment selection, and disease monitoring. Its flagship products, including Guardant360 and Guardant Shield, enable early detection, biomarker profiling, and real-time monitoring, supporting personalized cancer care. While we acknowledge the potential of GH as an investment, we believe certain AI stocks offer gr
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant nabs approval for Guardant360 companion diagnostic for Braftovi [Seeking Alpha]Seeking Alpha
- Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal CancerBusiness Wire
- Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart PlatformBusiness Wire
- Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth [Seeking Alpha]Seeking Alpha
GH
Earnings
- 10/29/25 - Beat
GH
Sec Filings
- 1/21/26 - Form 144
- 1/20/26 - Form 4
- 1/16/26 - Form 4
- GH's page on the SEC website